Mineralocorticoid Accelerates Transition to Heart Failure With Preserved Ejection Fraction Via “Nongenomic Effects”
- 27 July 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 122 (4), 370-378
- https://doi.org/10.1161/circulationaha.109.915215
Abstract
Background— Mechanisms promoting the transition from hypertensive heart disease to heart failure with preserved ejection fraction are poorly understood. When inappropriate for salt status, mineralocorticoid (deoxycorticosterone acetate) excess causes hypertrophy, fibrosis, and diastolic dysfunction. Because cardiac mineralocorticoid receptors are protected from mineralocorticoid binding by the absence of 11-β hydroxysteroid dehydrogenase, salt-mineralocorticoid–induced inflammation is postulated to cause oxidative stress and to mediate cardiac effects. Although previous studies have focused on salt/nephrectomy in accelerating mineralocorticoid-induced cardiac effects, we hypothesized that hypertensive heart disease is associated with oxidative stress and sensitizes the heart to mineralocorticoid, accelerating hypertrophy, fibrosis, and diastolic dysfunction. Methods and Results— Cardiac structure and function, oxidative stress, and mineralocorticoid receptor–dependent gene transcription were measured in sham-operated and transverse aortic constriction (studied 2 weeks later) mice without and with deoxycorticosterone acetate administration, all in the setting of normal-salt diet. Compared with sham mice, sham plus deoxycorticosterone acetate mice had mild hypertrophy without fibrosis or diastolic dysfunction. Transverse aortic constriction mice displayed compensated hypertensive heart disease with hypertrophy, increased oxidative stress (osteopontin and NOX4 gene expression), and normal systolic function, filling pressures, and diastolic stiffness. Compared with transverse aortic constriction mice, transverse aortic constriction plus deoxycorticosterone acetate mice had similar left ventricular systolic pressure and fractional shortening but more hypertrophy, fibrosis, and diastolic dysfunction with increased lung weights, consistent with heart failure with preserved ejection fraction. There was progressive activation of markers of oxidative stress across the groups but no evidence of classic mineralocorticoid receptor–dependent gene transcription. Conclusions— Pressure-overload hypertrophy sensitizes the heart to mineralocorticoid excess, which promotes the transition to heart failure with preserved ejection fraction independently of classic mineralocorticoid receptor–dependent gene transcription.Keywords
This publication has 46 references indexed in Scilit:
- Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart FailureCirculation, 2007
- Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blockerAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Rapid actions of aldosterone in vascular health and disease—friend or foe?Pharmacology & Therapeutics, 2006
- Regulation of cardiac hypertrophy by intracellular signalling pathwaysNature Reviews Molecular Cell Biology, 2006
- Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2006
- Mononuclear Leukocyte Mineralocorticoid ReceptorsHypertension, 2006
- Aldosterone Synthesis and Cytokine Production in Human Peripheral Blood Mononuclear CellsJournal of Pharmacological Sciences, 2006
- Calcium paradox of aldosteronism and the role of the parathyroid glandsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- The Mineralocorticoid Receptor: A Journey Exploring Its Diversity and Specificity of ActionMolecular Endocrinology, 2005
- Efficacy of aldosterone receptor antagonism in heart failure: Potential mechanismsCurrent Heart Failure Reports, 2004